ClinicalTrials.gg
RecruitingNCT04068012Updated Apr 14, 2026

Clinical Decision Support Tool in PARDS Pilot Study

An interventional study of Ventilator protocol in Ventilation Therapy; Complications, Ventilator-Induced Lung Injury and Ards, sponsored by Children's Hospital Los Angeles. Recruiting at 8 sites in 3 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Children's Hospital Los Angeles · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Ventilator-Induced Lung Injury with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Ventilator-Induced Lung Injury · United States.

Planned enrollment
4th of 18
180 · median 31
Started
2020
with 1 other
No phase
14 of 23
3 open now
Registered
12th of 23
by date
Lead sponsor
2 of 23
Children's Hospital Los Angeles

Among the 23 studies in Ventilator-Induced Lung Injury with a site in United States, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2020, is one of 14 with no phase, and was the 12th registered.

Ventilator-Induced Lung Injury

122 studies on the registry are indexed under Ventilator-Induced Lung Injury; 40 are open to participants now.

Browse Ventilator-Induced Lung Injury studies →

Open to participants now

4 of the 23 studies in Ventilator-Induced Lung Injury with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Ventilator-Induced Lung Injury studies recruiting now, 15 (68%) set no upper age limit and 5 (23%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Ventilator-Induced Lung Injury with a site in United States, or all of them as a file.
02

Study summary

Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS).

This will be accomplished by using CDS tools developed and deployed in Children's Hospital Los Angeles (CHLA) which are based on the best available pediatric evidence, and are currently being used in an NHLBI funded single center randomized controlled trial (NCT03266016, PI: Khemani). Without CDS, there is significant variability in ventilator management of PARDS patients both between and within Pediatric ICUs (PICUs), but clinicians are willing to accept CDS recommendations. The CDS tool will be deployed in multiple PICUs, targeting enrollment of up to 180 children with PARDS. Study hypotheses:

  1. The CDS tool in will be implementable in nearly all participating sites
  2. There will be > 80% compliance with CDS recommendations and
  3. The investigators can implement automatic data capture and entry in many of the ICUs

Once feasibility of this CDS tool is demonstrated, a multi-center validation study will be designed, which seeks to determine whether the CDS can result in a significant reduction in length of mechanical ventilation (LMV).

Read the detailed description

The central hypothesis is that CDS will help standardize ventilator management consistent with evidence-based recommendations leading to shorter LMV by limiting VILI (Ventilator Induced Lung Injury), preventing VIDD (Ventilator Induced Diaphragm Dysfunction) and allowing earlier recognition that patients are ready for liberation from the ventilator. However, key questions must be addressed prior to wide dissemination of this CDS tool:

Specific Aim 1: To assess the feasibility of implementing a web-based, de-identified CDS tool for MV in pediatric ARDS in multiple PICUs. Hypothesis: this CDS tool will be implementable in all PICUs to function consistent with each hospital's specific Information Technology (IT) capabilities.

Specific Aim 2: To assess the acceptability and compliance with recommendations from the CDS tool related to oxygenation, ventilation, weaning and extubation readiness testing in PARDS patients at each of the participating PICUs (anticipated 20 patients enrolled per site). Hypothesis: over time, adherence with recommendations in each of these domains will exceed 80% in all PICUs.

Specific Aim 3: To implement methods for automated data capture within CDS to provide the right information, to the right person, using the right format, in the right channel and at the right time during workflow ("CDS Five Rights") framework, which can be adapted to the individual IT capabilities at each hospital. Hypothesis: Over 90% of necessary data can be pulled into the CDS in an automated fashion in sites which have access to electronic data capture of ventilator settings and blood gases.

Patients will be managed on the eVentilator protocol (the CDS tool), through the acute, stable and weaning phases of mechanical ventilation, including Spontaneous Breathing tests (SBTs) and Extubation Readiness tests.

Data will be qualitatively assessed for implementation barriers. Acceptance and rejection and mode stratification will be examined. Data needed for the CDS protocol will be available electronically or can be interfaced through the bedside monitor.

Patients will be on the CDS protocol, as intent to treat, while patient is on invasive mechanical ventilation, capped at 28 days, limitation of care, or death, whichever comes first.

03

Conditions studied

  • Ventilation Therapy; Complications
  • Ventilator-Induced Lung Injury
  • Ards
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children > 1 month of age and >44 weeks gestation and ≤ 18 years of age AND
  • Supported on mechanical ventilation with pulmonary parenchymal disease (i.e. Pediatric Acute Respiratory Distress Syndrome (PARDS)) with Oxygen Saturation Index (OSI) ≥ 5) or Oxygenation Index (OI) ≥ 4 AND
  • Who are within 72 hours of initiation of invasive mechanical ventilation AND
  • Who are anticipated to require >72 hours mechanical ventilation.

Exclusion criteria

Exclusion Criteria:

  • Conditions on enrollment that preclude conventional methods of weaning (i.e., status asthmaticus, severe lower airway obstruction, bronchiolitis, critical airway, Extra Corporeal Life Support (ECLS), intubation for Upper Airway Obstruction, Do Not Resuscitate orders, severe chronic respiratory failure, spinal cord injury above lumbar region, cyanotic heart disease (unrepaired or palliated)) OR
  • Conditions precluding the use of permissive hypercapnia or hypoxemia (i.e. intracranial hypertension, severe pulmonary hypertension)
  • Primary Attending physician refuses to enroll the patient
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Intervention

    Ventilator management using the proposed protocol in both acute and weaning phases

    Other: Ventilator protocol

Interventions

  • OtherVentilator protocol

    open loop ventilator management by a computer based protocol

06

What researchers measure

Primary outcomes

  1. Aim 1: Implementation Feasibility

    The main outcome for Aim 1 is the ability to install the CDS tool in at least 7 of the 9 potential institutions and get data from each of the minimum of 140 patients anticipated to be enrolled. The survey data will be qualitatively assessed for themes related to barriers to implementation and consider this in future refinements of the CDS tool.

    Time frame: through study completion - each patient will be capped at 28 days, limitation of care, or death, whichever comes first.

  2. Aim 2: Protocol Adherence

    Acceptance of recommendations (between 75-85%) will be the main outcome used to determine correctness of interpretation and acceptability of the CDS Tool.

    Time frame: through study completion - each patient will be capped at 28 days, limitation of care, or death, whichever comes first.

07

Study locations

6 of 8 sites recruiting
08

References and documents

Publications

  • Hotz JC, Bornstein D, Kohler K, Smith E, Suresh A, Klein M, Bhalla A, Newth CJ, Khemani RG. Real-Time Effort Driven Ventilator Management: A Pilot Study. Pediatr Crit Care Med. 2020 Nov;21(11):933-940. doi: 10.1097/PCC.0000000000002556. PubMed 32976348 ↗
  • Khemani RG, Hotz JC, Klein MJ, Kwok J, Park C, Lane C, Smith E, Kohler K, Suresh A, Bornstein D, Elkunovich M, Ross PA, Deakers T, Beltramo F, Nelson L, Shah S, Bhalla A, Curley MAQ, Newth CJL. A Phase II randomized controlled trial for lung and diaphragm protective ventilation (Real-time Effort Driven VENTilator management). Contemp Clin Trials. 2020 Jan;88:105893. doi: 10.1016/j.cct.2019.105893. Epub 2019 Nov 16. PubMed 31740425 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Jul 2027, 79 months after the start.

Of 40 interventional studies with no phase under Ventilator-Induced Lung Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 53. This study's planned 79 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2019
First posted
Aug 28, 2019
StartActual
Dec 1, 2020
Primary completionEst.
Jul 2027
CompletionEst.
Jul 1, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04068012
Responsible party
Christopher J. L. Newth, MD (Principal Investigator, Children's Hospital Los Angeles) — Principal investigator
First posted
Aug 28, 2019
Start date
Dec 1, 2020
Primary completion
Jul 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Christopher J Newth, MD
Contact
cnewth@chla.usc.edu
3233612557
Robinder G Khemani, MD
Contact
rkhemani@chla.usc.edu
3233612376
Christopher J Newth, MD
principal investigator · Children's Hospital Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion